Efficacy of Saccharomyces boulardii CNCM I-745 probiotic drug in the prevention and treatment of diarrhea in hospitalized patients with new coronavirus infection COVID-19
- Authors: Maev I.V.1, Andreev D.N.1, Sokolov P.S.1, Fomenko A.К.1, Devkota M.K.1, Andreev N.G.1, Zaborovsky A.V.1
-
Affiliations:
- Yevdokimov Moscow State University of Medicine and Dentistry
- Issue: Vol 94, No 10 (2022)
- Pages: 1163-1170
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/114789
- DOI: https://doi.org/10.26442/00403660.2022.10.201881
- ID: 114789
Cite item
Full Text
Abstract
Aim. To evaluate the efficacy of Saccharomyces boulardii (S. boulardii) CNCM I-745 probiotic drug in preventing and treating diarrhea in hospitalized patients with COVID-19.
Materials and methods. A prospective comparative study was conducted in two parallel groups. The study included males and females aged 18 to 60 with the following diagnosis confirmed by polymerase chain reaction: U07.2 Coronavirus infection COVID-19, caused by SARS-CoV-2 virus (grade 1–3 pneumonia according to CT scan). All patients received antibiotic therapy. The patients were subdivided into two equal groups (n=60) depending on the administration of S. boulardii CNCM I-745 probiotic drug in addition to standard treatment. The probiotic was prescribed by the attending physician; the dose was 2 capsules per day (500 mg/day) 30 min before the meal for 10 days. All patients were monitored for main clinical, laboratory, and instrumental parameters during the study. In addition, the symptom of diarrhea (stool with a frequency of more than 3 times a day of type 6 and 7 according to the Bristol stool scale), including its frequency, duration, and the number of bowel movements of loose stool per day were precisely evaluated in both groups.
Results. In the overall patient pool, diarrhea was reported in 21.7% of in-patients during the observation period (95% confidence interval [CI] 14.2–29.1) with a mean duration of 4.6154 days (95% CI 3.7910-5.4398). The incidence of diarrhea in group 1 was 13.3% (95% CI 4.5–22.2), and in group 2, it was 30.0% (95% CI 18.1–41.9). Relative risk showed that the use of the S. boulardii CNCM I-745 probiotic drug leads to a significant reduction in the risk of diarrhea in hospitalized patients with COVID-19 infection receiving antibiotic therapy (odds ratio [OR] 0.3590, 95% CI 0.1421–0.9069; p=0.0303). In group 1, the duration of diarrhea was 3.1250 days (95% CI 2.5892–3.6608) versus 5.2778 days (95% CI 4.2290–6.3265) in group 2, p=0.0112. The mean daily frequency of loose stools in patients with diarrhea in group 1 was 3.2500 (95% CI 2.6588–3.8412) versus 4.3889 (95% CI 3.7252–5.0525) in group 2, p=0.0272. The secondary endpoint, duration of hospital stay, was also significantly shorter in group 1 patients — 11.6833 days (95% CI 11.2042–12.1625) versus 12.7333 days (95% CI 12.1357–13.3309) in group 2, p=0.0120.
Conclusion. The present prospective comparative study demonstrated that adding S. boulardii CNCM I-745 probiotic drug into the standard treatment regimen of patients with new coronavirus infection COVID-19 receiving antibiotic therapy helps reduce the incidence of diarrhea and its severity during hospitalization, as well as the duration of hospital stay.
Full Text
##article.viewOnOriginalSite##About the authors
Igor V. Maev
Yevdokimov Moscow State University of Medicine and Dentistry
Email: azabor@mail.ru
ORCID iD: 0000-0001-6114-564X
акад. РАН, д-р мед. наук, проф., зав. каф. пропедевтики внутренних болезней и гастроэнтерологии
Russian Federation, MoscowDmitry N. Andreev
Yevdokimov Moscow State University of Medicine and Dentistry
Email: azabor@mail.ru
ORCID iD: 0000-0002-4007-7112
канд. мед. наук, доц., доц. каф. пропедевтики внутренних болезней и гастроэнтерологии
Russian Federation, MoscowPhilipp S. Sokolov
Yevdokimov Moscow State University of Medicine and Dentistry
Email: azabor@mail.ru
ORCID iD: 0000-0003-2813-6498
врач-специалист отд-ния микробиологического анализа Клинического центра COVID-19, преподаватель каф. фармакологии
Russian Federation, MoscowAleksei К. Fomenko
Yevdokimov Moscow State University of Medicine and Dentistry
Email: azabor@mail.ru
ORCID iD: 0000-0002-1794-7263
врач-специалист отд-ния микробиологического анализа Клинического центра COVID-19, преподаватель каф. фармакологии
Russian Federation, MoscowMikhail K. Devkota
Yevdokimov Moscow State University of Medicine and Dentistry
Email: azabor@mail.ru
ORCID iD: 0000-0002-3736-4196
врач-специалист отд-ния микробиологического анализа Клинического центра COVID-19, преподаватель каф. фармакологии
Russian Federation, MoscowNikolai G. Andreev
Yevdokimov Moscow State University of Medicine and Dentistry
Email: azabor@mail.ru
ORCID iD: 0000-0002-5136-0140
канд. мед. наук, доц. каф. пропедевтики внутренних болезней и гастроэнтерологии
Russian Federation, MoscowAndrew V. Zaborovsky
Yevdokimov Moscow State University of Medicine and Dentistry
Author for correspondence.
Email: azabor@mail.ru
ORCID iD: 0000-0002-7923-9916
д-р мед. наук, доц., зав. каф. фармакологии
Russian Federation, MoscowReferences
- Маев И.В., Шпектор А.В., Васильева Е.Ю., и др. Новая коронавирусная инфекция COVID-19: экстрапульмональные проявления. Терапевтический архив. 2020;92(8):4-11 [Maev IV, Shpektor AV, Vasilyeva EYu, et al. Novel coronavirus infection COVID-19: extrapulmonary manifestations. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(8):4-11 (in Russian)]. doi: 10.26442/00403660.2020.08.000767
- Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. doi: 10.1056/NEJMoa2001017
- Wu Y-C, Chen C-S, Chan Y-J. The outbreak of COVID-19: an overview. J Chinese Med Assoc. 2020;83(3):217-220. doi: 10.1097/JCMA.0000000000000270
- Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109(3):102433. doi: 10.1016/j.jaut.2020.102433
- Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus Pandemic (COVID-19). Available at: https://ourworldindata.org/coronavirus. Accessed: 31.07.2022.
- Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. doi: 10.1056/NEJMoa2002032
- Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577-82. doi: 10.7326/M20-0504
- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020;323(13):1239. doi: 10.1001/jama.2020.2648
- Zheng Z, Peng F, Xu B, et al. Risk factors of critical and mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16-e25. doi: 10.1016/j.jinf.2020.04.021
- Янушевич О.О., Маев И.В., Крихели Н.И., и др. Распространенность и прогностическое значение гастроэнтерологических проявлений COVID-19: данные Российской университетской клиники. Терапевтический архив. 2021;93(8):853-61 [Ianushevich OO, Maev IV, Krikheli NI, et al. Prevalence and prognostic value of gastroenterological manifestations of COVID-19: data from the Russian University Clinic. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(8):853-61 (in Russian)]. doi: 10.26442/00403660.2021.08.200977
- Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(7):667-78. doi: 10.1016/S2468-1253(20)30126-6
- Shih AR, Misdraji J. COVID-19: gastrointestinal and hepatobiliary manifestations. Hum Pathol. 2022;5(7):667-78. doi: 10.1016/j.humpath.2022.07.006
- Ozkurt Z, Çınar Tanrıverdi E. COVID-19: Gastrointestinal manifestations, liver injury and recommendations. World J Clin Cases. 2022;10(4):1140-63. doi: 10.12998/wjcc.v10.i4.1140
- Maslennikov R, Poluektova E, Ivashkin V, Svistunov A. Diarrhoea in adults with coronavirus disease – beyond incidence and mortality: a systematic review and meta-analysis. Infect Dis (Auckl). 2021;53(5):348-60. doi: 10.1080/23744235.2021.1885733
- Beaugerie L, Petit J-C. Antibiotic-associated diarrhoea. Best Pract Res Clin Gastroenterol. 2004;18(2):337-52. doi: 10.1016/j.bpg.2003.10.002
- Mateen BA, Samanta S, Tullie S, et al. Diarrhoea and preadmission antibiotic exposure in COVID-19: a retrospective cohort study of 1153 hospitalised patients. BMJ Open Gastroenterol. 2021;8(1):e000593. doi: 10.1136/bmjgast-2020-000593
- Маев И.В., Дичева Д.Т., Андреев Д.Н. Применение Saccharomyces boulardii в современной клинической практике. Consilium Medicum. 2013;15(8):35-8 [Maev IV, Dicheva DT, Andreev DN. Application of Saccharomyces boulardii in modern clinical practice. Consilium Medicum. 2013;15(8):35-8 (in Russian)].
- McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010;16(18):2202. doi: 10.3748/wjg.v16.i18.2202
- Szajewska H, Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2015;42(7):793-801. doi: 10.1111/apt.13344
- Dinleyici EC, Eren M, Ozen M, et al. Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. Expert Opin Biol Ther. 2012;12(4):395-410. doi: 10.1517/14712598.2012.664129
- McFarland LV, Evans CT, Goldstein EJC. Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. Front Med. 2018;5:124. doi: 10.3389/fmed.2018.00124
- Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 15 (22.02.2022). Режим доступа: https://static0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/ВМР_COVID-19_V15.pdf. Ссылка активна на 25.09.2022 [Vremennye metodicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Versiia 15 (22.02.2022). Available at: https://static0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/ВМР_COVID-19_V15.pdf. Accessed: 05.05.2022 (in Russian)].
- Elshazli RM, Kline A, Elgaml A, et al. Gastroenterology manifestations and COVID-19 outcomes: а meta-analysis of 25,252 cohorts among the first and second waves. J Med Virol. 2021;93(5):2740-68. doi: 10.1002/jmv.26836
- Palacios Cruz M, Santos E, Velázquez Cervantes MA, León Juárez M. COVID-19, a worldwide public health emergency. Rev Clínica Española (English Ed). 2021;221(1):55-61. doi: 10.1016/j.rceng.2020.03.001
- Parasher A. COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J. 2021;97(1147):312-20. DOI:0.1136/postgradmedj-2020-138577
- Mandal A, Konala VM, Adapa S, et al. Gastrointestinal manifestations in COVID-19 infection and its practical applications. Cureus. 2020;12(6):e8750. doi: 10.7759/cureus.8750
- Mitsuyama K, Tsuruta K, Takedatsu H, et al. Clinical features and pathogenic mechanisms of gastrointestinal injury in COVID-19. J Clin Med. 2020;9(11):3630. doi: 10.3390/jcm9113630
- Megyeri K, Dernovics Á, Al-Luhaibi ZII, Rosztóczy A. COVID-19-associated diarrhea. World J Gastroenterol. 2021;27(23):3208-22. doi: 10.3748/wjg.v27.i23.3208
- Zimmermann P, Curtis N. The effect of antibiotics on the composition of the intestinal microbiota – a systematic review. J Infect. 2019;79(6):471-89. doi: 10.1016/j.jinf.2019.10.008
- Myllyluoma E, Ahlroos T, Veijola L, et al. Effects of anti-Helicobacter pylori treatment and probiotic supplementation on intestinal microbiota. Int J Antimicrob Agents. 2007;29(1):66-72. doi: 10.1016/j.ijantimicag.2006.08.034
- Ye Q, Shao X, Shen R, et al. Changes in the human gut microbiota composition caused by Helicobacter pylori eradication therapy: a systematic review and meta-analysis. Helicobacter. 2020:e12713. doi: 10.1111/hel.12713
- Mohsen S, Dickinson JA, Somayaji R. Update on the adverse effects of antimicrobial therapies in community practice. Can Fam Physician. 2020;66(9):651-9.
- Guo Q, Goldenberg JZ, Humphrey C, et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019;4(4):CD004827. doi: 10.1002/14651858
- Tariq R, Yadav D, Tahir MW, et al. S136 Efficacy of Saccharomyces boulardii for prevention of Clostridioides difficile infection: a systematic review and meta-analysis. Am J Gastroenterol. 2021;116(1):S59-S60. doi: 10.14309/01.ajg.0000773016.43460.eb
Supplementary files
![](/img/style/loading.gif)